- About About
Medical Patient Resources Becoming a State-Authorized Patient Talking to your doctor The Medical Cannabis Patient’s Guide for U.S. Travel Patient's Guide to CBD Patient's Guide to Medical Cannabis Guide to Using Medical Cannabis Condition-based Booklets Growing Cannabis Cannabis Tincture, Salve, Butter and Oil Recipes Leaf411 Affordability Program Tracking Treatment & Gathering Data with Releaf App Medical Professional Resources CME for Medical Professionals Cannabis Safety Medical Cannabis Research
- Legal Legal
Advocacy ASA Chapters Start an ASA Chapter Take Action Campaigns No Patient Left Behind End Pain, Not Lives Vote Medical Marijuana Medical Cannabis Advocate's Training Center Resources for Tabling and Lobby Days Strategic Planning Civics 101 Strategic Messaging Citizen Lobbying Participating in Implementation Movement Building Organizing a Demonstration Organizing Turnout for Civic Meetings Public Speaking Media 101 Patient's History of Medical Cannabis
Policy Model Federal Legislation Download Ending The Federal Conflict Public Comments by ASA Industry Standards Guide to Regulating Industry Standards Recognizing Science using the Data Quality Act Fact Sheet on ASA's Data Quality Act Petition to HHS Data Quality Act Briefs ASA Data Quality Act petition to HHS Information on Lawyers and Named Patients in the Data Quality Act Lawsuit Reports 2020 State of the States Medical Cannabis Access for Pain Treatment Medical Cannabis in America
- Join Join
Recommending Cannabis in Oklahoma
Any physician licensed by the State Board of Medical Licensure and Supervision or the State Board of Osteopathic Examiners that practices in Oklahoma may serve as the principal investigator in clinical trials with CBD oil. The physician must:
- Apply to and be approved by the FDA as principal investigator for the state-wide investigation of a new drug application.
- Receive a license from DEA.
- Receive a registration from Oklahoma State Bureau of Narcotics and Dangerous Drugs Control.
The physician may include subinvestigators who meet the criteria in the second and third bullet point to participate in the clinical trial.
In addition, any person with a written certification from a physician licensed in Oklahoma that the person suffers from a severe form of epilepsy that is not adequately treated by traditional medical therapies, spasticity due to multiple sclerosis or paraplegia, intractable nausea and vomiting or appetite stimulation with chronic wasting diseases is exempt from criminal prosecution for possession of CBD oil.